Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood
Hwa Young Kim, Jung Min Ko
Ann Pediatr Endocrinol Metab. 2022;27(2):90-97.   Published online 2022 Jun 30     DOI:
Citations to this article as recorded by Crossref logo
Skeletal overgrowth in a pre-pubescent child treated with pan-FGFR inhibitor
Fataneh Majlessipour, Gaohui Zhu, Nicole Baca, Meenasri Kumbaji, Vivian Hwa, Moise Danielpour
Heliyon.2024; 10(11): e30887.     CrossRef
Integrated Analysis of Transcriptome Expression Profiles Reveals miRNA-326–NKX3.2-Regulated Porcine Chondrocyte Differentiation
Qiao Xu, Yabiao Luo, Zhe Chao, Jibin Zhang, Ximing Liu, Qiguo Tang, Kejun Wang, Shuyi Tan, Meiying Fang
International Journal of Molecular Sciences.2023; 24(8): 7257.     CrossRef
Genetic diagnosis of skeletal dysplasias causing short stature in children
Inusha Panigrahi, Roshan Daniel, Karandeep Kaur
Journal of Pediatric Endocrinology and Diabetes.2023; 3: 9.     CrossRef
Molecular mechanisms of long bone growth and chondrocyte regulation: A narrative review
Eungu Kang
Precision and Future Medicine.2023; 7(3): 123.     CrossRef
Cell-based screen identifies porphyrins as FGFR3 activity inhibitors with therapeutic potential for achondroplasia and cancer
Yun-Wen Lin, Hsiao-Jung Kao, Wei-Ting Chen, Cheng-Fu Kao, Jer-Yuarn Wu, Yuan-Tsong Chen, Yi-Ching Lee
JCI Insight.2023;[Epub]     CrossRef
A new era of genetic diagnosis for short stature children: A review
Yoo-Mi Kim
Precision and Future Medicine.2022; 6(4): 218.     CrossRef